|Awarded On||November 02, 2011|
|Title||A New Role for Triptan Drugs in the Treatment of Breast Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Kevin N Dalby|
Through a joint translational drug discovery effort the Dalby and Ozpolat laboratories recently discovered a potential new role for an established class of drug in the treatment of breast cancer. We discovered that a member of this drug class showed promising anticancer properties in models of human breast cancer. Significantly, we found evidence for previously unknown signaling pathways in estrogen receptor ER(-), ER(+), triple negative, highly aggressive metastatic and drug resistant (tamoxifen and chemotherapy) breast cancers, which could be exploited therapeutically. Based on our preliminary results we hypothesize that the targeting of a specific receptor, that we discovered to be over-e...